Santen Pharmaceutical
4536.TTSE PRIMEPharmaceutical
Filed as SANTEN PHARMACEUTICAL CO., LTD. (2022-06–2026-06)
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥291.6bn | ¥300.0bn | ¥302.0bn | ¥279.0bn | ¥266.3bn | ¥249.6bn |
| Operating income | ¥47.8bn | ¥46.9bn | ¥38.5bn | −¥3.1bn | ¥35.9bn | ¥12.2bn |
| Net income (owners) | ¥37.4bn | ¥36.3bn | ¥26.6bn | −¥14.9bn | ¥27.2bn | ¥9.3bn |
| Total assets | ¥423.0bn | ¥409.3bn | ¥435.7bn | ¥421.2bn | ¥460.0bn | ¥405.3bn |
| Net assets / equity | ¥296.0bn | ¥285.2bn | ¥305.4bn | ¥293.3bn | ¥336.8bn | ¥309.6bn |
| Operating cash flow | ¥43.5bn | ¥60.9bn | ¥72.6bn | ¥37.1bn | ¥46.0bn | ¥38.8bn |
| EPS (basic) | ¥114.04 | ¥103.98 | ¥72.59 | ¥-38.6 | ¥68.07 | ¥23.3 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 209 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 80 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 209 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 80 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 209 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 102 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 102 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 80 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 209 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 102 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 102 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 80 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 210 figures · EDINET |
21 more reports are still being processed.